Inclusion Criteria:

1. Have histologically or cytologically confirmed cutaneous squamous cell carcinoma
(CSCC) that is not amenable to curative therapy. If the biopsy was collected outside
of MDACC, the MDACC Pathology Department must assess and confirm the SCC diagnosis.

2. Have measurable disease.

3. Be at least 18 years of age.

4. Have ECOG performance status 0-2.

5. Must have ability to understand and the willingness to sign a written Informed
Consent Document (ICD). In the event that non-English speaking participants are
eligible for this study, a short form (if applicable) or an ICD in their language
will be utilized and completed in accordance with the MDACC "Policy For Consenting
Non-English Speaking Participants."

6. Must have adequate organ and marrow function as follows:(a) leukocytes >/= 3,000/mm^3
(b) absolute neutrophil count >/= 1,500/mm^3 (c) platelets >/= 75,000/mm^3 (d)
hemoglobin >/= 8g/dL (e) total bilirubin (ULN) (f) AST(SGOT)/ALT(SGPT) alkaline phosphatase ULN or creatinine clearance >/= 60 mL/min/1.73 m^2

7. Prior radiotherapy is allowed if: (a) there is measurable disease outside the
radiation field OR (b) radiotherapy was completed more than 4 weeks ago and there is
clearly recurrent and growing disease within the radiation field.

8. Must be able to take intact tablets by mouth, or be able to take tablets dissolved in
water by mouth or by a percutaneous gastrostomy tube.

9. Patients - both males and females - with reproductive potential (includes women who
are menopausal for less than 1 year and not surgically sterilized) must practice
effective contraceptive measures such as barrier methods, condom or diaphragm with
spermicide, or abstinence throughout the study. Birth control should continue for 4
weeks after discontinuation of erlotinib therapy. Women of childbearing potential
must provide a negative pregnancy test (serum betaHCG) within 72 hours prior to first
receiving protocol therapy.

10. Organ transplant patients are eligible as long as they do not have active signs of
rejection and have adequate bone marrow function.

Exclusion Criteria:

1. Women who are pregnant, breastfeeding, and women and men not practicing effective
birth control. Erlotinib is a signal transduction inhibitor agent with the potential
for teratogenic or abortifacient effects. There is an unknown but potential risk for
adverse events in nursing infants secondary to treatment of the mother with
erlotinib. Breastfeeding should be discontinued if the mother is treated with
erlotinib.

2. Prior EGFR inhibitor therapy is not allowed (including, but not limited to,
erlotinib, gefitinib, cetuximab, panitumumab, vandetanib).

3. Patients who are receiving any other anticancer or investigational agents at time of
study enrollment. Patients may have received one other systemic therapy or
investigational agent in the past, but a washout time period of at least 4 weeks and
recovery of any treatment-related toxicities to < CTCAEv4 grade 2 is required.

4. History of allergic reactions attributed to compounds of similar chemical or biologic
composition to erlotinib.

5. Patients with a history of an invasive malignancy (other than the one treated in this
study) or lymphoproliferative disorder within the past 3 years. Patients with a
history of adequately treated non-melanoma skin cancer, ductal carcinoma in situ of
the breast, or carcinoma in situ of the cervix are allowed.

6. Patients with incomplete healing from previous surgery.

7. Patients with pulmonary fibrosis (other than in a radiated field) or active
interstitial lung disease.

8. Patients with active gastrointestinal disease or a disorder that alters
gastrointestinal motility or absorption, including lack of integrity of the
gastrointestinal tract (for example, a significant surgical resection of the stomach
or small bowel, inflammatory bowel disease or uncontrolled chronic diarrhea.

9. Patients with skin rash ≥ CTCAEv4 grade 2

10. In the opinion of the investigator, patients with any condition that is unstable or
could jeopardize the safety of the patient or could limit compliance with the study's
requirements. These include, but are not limited to, ongoing or active infection
requiring parenteral antibiotics at time of study registration, psychiatric illness
that would limit compliance with study requirements or symptomatic congestive heart
failure (NYHA class II or greater), unstable angina pectoris or cardiac arrhythmia
requiring maintenance medication.

11. Patient is unwilling or unable to discontinue prohibited concomitant therapies, (i.e
St. John's wort, grapefruit juice, H2 blockers/proton pump inhibitors, strong CYP3A4
inhibitors and inducers).